^
    Back
    Association details:
    Biomarker:IRF4 mutation
    Cancer:Diffuse Large B Cell Lymphoma
    Regimen: (cyclophosphamide + doxorubicin hydrochloride + prednisone + Rituxan (rituximab) + vincristine)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ICML 2023
    Title:

    EXPLORING DIFFERENTIAL MUTATIONAL DISTRIBUTION BY TARGETED SEQUENCING IN A R-CHOP TREATED COHORT OF DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS

    Published date:
    06/09/2023
    Excerpt:
    A cohort of 105 de novo DLBCL pts, uniformly treated with first-line R-CHOP, were studied...a subgroup of DHB pts characterized by mutations in MYC, PRDM1, or IRF4 (n = 15) had markedly inferior OS (5-year OS, log-rank, p = 0.0003, HR 3.34) compared to negative non-DHB pts (n = 55) or negative non-DHB/DHB pts (p = 0.0017, HR 2.7, n = 72).
    DOI:
    https://doi.org/10.1002/hon.3165_505